Jaguar Animal Health (NASDAQ:JAGX) Announces Earnings Results, Beats Estimates By $135.50 EPS

Jaguar Animal Health (NASDAQ:JAGX) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($13.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($149.10) by $135.50, FiscalAI reports. The company had revenue of $20.27 million for the quarter, compared to analysts’ expectations of $4.21 million. Jaguar Animal Health had a negative net margin of 464.20% and a negative return on equity of 1,194.94%.

Jaguar Animal Health Stock Performance

Shares of NASDAQ:JAGX traded up $0.31 during trading on Wednesday, hitting $3.67. The company’s stock had a trading volume of 29,978 shares, compared to its average volume of 93,845. The company has a 50-day moving average of $11.69 and a 200-day moving average of $28.22. Jaguar Animal Health has a 12 month low of $2.53 and a 12 month high of $186.55. The company has a debt-to-equity ratio of 4.08, a current ratio of 0.50 and a quick ratio of 0.29. The firm has a market cap of $1.37 million, a price-to-earnings ratio of 0.00 and a beta of 0.01.

Wall Street Analysts Forecast Growth

JAGX has been the topic of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of Jaguar Animal Health from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 10th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.